Daesung Microbiological Labs. Co. Ltd (036480) - Net Assets
Based on the latest financial reports, Daesung Microbiological Labs. Co. Ltd (036480) has net assets worth ₩35.42 Billion KRW (≈ $24.00 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₩57.98 Billion ≈ $39.29 Million USD) and total liabilities (₩22.56 Billion ≈ $15.29 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 036480 strategic assets to equity ratio to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₩35.42 Billion |
| % of Total Assets | 61.09% |
| Annual Growth Rate | 4.6% |
| 5-Year Change | -4.28% |
| 10-Year Change | 22.09% |
| Growth Volatility | 6.65 |
Daesung Microbiological Labs. Co. Ltd - Net Assets Trend (2012–2025)
This chart illustrates how Daesung Microbiological Labs. Co. Ltd's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see 036480 company net worth.
Annual Net Assets for Daesung Microbiological Labs. Co. Ltd (2012–2025)
The table below shows the annual net assets of Daesung Microbiological Labs. Co. Ltd from 2012 to 2025. Also explore Daesung Microbiological Labs. Co. Ltd annual equity growth to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | ₩35.42 Billion ≈ $24.00 Million |
+0.77% |
| 2024-12-31 | ₩35.15 Billion ≈ $23.82 Million |
-5.89% |
| 2023-12-31 | ₩37.35 Billion ≈ $25.31 Million |
-3.83% |
| 2022-12-31 | ₩38.84 Billion ≈ $26.32 Million |
+4.96% |
| 2021-12-31 | ₩37.00 Billion ≈ $25.08 Million |
+1.91% |
| 2020-12-31 | ₩36.31 Billion ≈ $24.61 Million |
+3.48% |
| 2019-12-31 | ₩35.09 Billion ≈ $23.78 Million |
+6.31% |
| 2018-12-31 | ₩33.01 Billion ≈ $22.37 Million |
+8.95% |
| 2017-12-31 | ₩30.30 Billion ≈ $20.53 Million |
+4.43% |
| 2016-12-31 | ₩29.01 Billion ≈ $19.66 Million |
+15.61% |
| 2015-12-31 | ₩25.09 Billion ≈ $17.01 Million |
+18.71% |
| 2014-12-31 | ₩21.14 Billion ≈ $14.32 Million |
+7.21% |
| 2013-12-31 | ₩19.72 Billion ≈ $13.36 Million |
-0.08% |
| 2012-12-31 | ₩19.73 Billion ≈ $13.37 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Daesung Microbiological Labs. Co. Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 109.9% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₩27.28 Billion | 77.01% |
| Other Components | ₩8.14 Billion | 22.99% |
| Total Equity | ₩35.42 Billion | 100.00% |
Daesung Microbiological Labs. Co. Ltd Competitors by Market Cap
The table below lists competitors of Daesung Microbiological Labs. Co. Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Orbital Corporation Ltd
AU:OEC
|
$15.84 Million |
|
Indian Terrain Fashions Limited
NSE:INDTERRAIN
|
$15.84 Million |
|
PRI EKOPARK SA ZY -10
F:NPA
|
$15.85 Million |
|
SYZYGY AG
XETRA:SYZ
|
$15.86 Million |
|
Good Times Restaurants Inc
NASDAQ:GTIM
|
$15.84 Million |
|
Organic Tea Cosmetics Holdings Company Limited
KQ:900300
|
$15.82 Million |
|
Alma Metals Ltd
AU:ALM
|
$15.81 Million |
|
Hanchang
KO:005110
|
$15.81 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Daesung Microbiological Labs. Co. Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 35,149,367,370 to 35,421,462,650, a change of 272,095,280 (0.8%).
- Net income of 598,188,050 contributed positively to equity growth.
- Dividend payments of 285,000,000 reduced retained earnings.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₩598.19 Million | +1.69% |
| Dividends Paid | ₩285.00 Million | -0.8% |
| Other Changes | ₩-41.09 Million | -0.12% |
| Total Change | ₩- | 0.77% |
Book Value vs Market Value Analysis
This analysis compares Daesung Microbiological Labs. Co. Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.66x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 0.81x to 0.66x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | ₩7634.61 | ₩6150.00 | x |
| 2017-12-31 | ₩7972.76 | ₩6150.00 | x |
| 2018-12-31 | ₩8686.65 | ₩6150.00 | x |
| 2019-12-31 | ₩9234.52 | ₩6150.00 | x |
| 2020-12-31 | ₩9555.62 | ₩6150.00 | x |
| 2021-12-31 | ₩9737.79 | ₩6150.00 | x |
| 2022-12-31 | ₩10220.37 | ₩6150.00 | x |
| 2023-12-31 | ₩9828.59 | ₩6150.00 | x |
| 2024-12-31 | ₩9249.83 | ₩6150.00 | x |
| 2025-12-31 | ₩9321.44 | ₩6150.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Daesung Microbiological Labs. Co. Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 1.69%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 2.30%
- • Asset Turnover: 0.45x
- • Equity Multiplier: 1.64x
- Recent ROE (1.69%) is below the historical average (5.99%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2014 | 9.66% | 8.07% | 0.91x | 1.31x | ₩-71.44 Million |
| 2015 | 18.13% | 14.67% | 0.96x | 1.29x | ₩2.04 Billion |
| 2016 | 15.49% | 14.59% | 0.87x | 1.23x | ₩1.59 Billion |
| 2017 | 5.14% | 6.48% | 0.69x | 1.15x | ₩-1.47 Billion |
| 2018 | 9.60% | 12.63% | 0.66x | 1.15x | ₩-130.80 Million |
| 2019 | 8.12% | 11.34% | 0.50x | 1.45x | ₩-659.14 Million |
| 2020 | 4.18% | 6.12% | 0.40x | 1.71x | ₩-2.11 Billion |
| 2021 | 2.34% | 3.61% | 0.38x | 1.69x | ₩-2.83 Billion |
| 2022 | 4.39% | 6.68% | 0.39x | 1.68x | ₩-2.18 Billion |
| 2023 | -1.82% | -2.66% | 0.40x | 1.72x | ₩-4.41 Billion |
| 2024 | -5.03% | -7.43% | 0.41x | 1.66x | ₩-5.28 Billion |
| 2025 | 1.69% | 2.30% | 0.45x | 1.64x | ₩-2.94 Billion |
Industry Comparison
This section compares Daesung Microbiological Labs. Co. Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $419,496,081,558
- Average return on equity (ROE) among peers: -4.68%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Daesung Microbiological Labs. Co. Ltd (036480) | ₩35.42 Billion | 9.66% | 0.64x | $15.84 Million |
| ORIENTBIO Inc. (002630) | $48.55 Billion | -31.47% | 0.47x | $73.37 Million |
| Green Cross (005250) | $1.38 Trillion | 3.43% | 0.63x | $290.81 Million |
| Green Cross Holdings Preference Shares (005257) | $1.51 Trillion | 0.20% | 0.84x | $2.97 Million |
| Pharmicell (005690) | $94.60 Billion | -0.72% | 0.08x | $509.52 Million |
| GeneOne Life Science Inc (011000) | $33.79 Billion | 0.00% | 0.20x | $32.81 Million |
| HLB Co. Ltd (028300) | $582.25 Billion | -32.21% | 0.29x | $2.67 Billion |
| Mgenplus Co. Ltd. (032790) | $44.12 Billion | 7.01% | 0.62x | $22.01 Million |
| Seoulin Bioscience Co.Ltd (038070) | $41.57 Billion | 10.01% | 0.45x | $24.32 Million |
| Hyundai Bioscience Co. Ltd (048410) | $46.99 Billion | 1.63% | 0.35x | $444.71 Million |
About Daesung Microbiological Labs. Co. Ltd
Daesung Microbiological Labs. Co., Ltd. manufactures and sells vaccines for swine, poultry, canine, cattle, and fish in South Korea. It offers antibiotics and antibacterials, parasiticides and disinfectants, probiotics and enzyme products, and nutrients and pharmaceuticals. The company also exports its products. Daesung Microbiological Labs. Co., Ltd. was founded in 1966 and is headquartered in U… Read more